anpac
bio
investee
company
china
received
nucleic
acid
test
certification
began
volume
tests
collaborations
anpac
bio
san
jose
globe
newswire
anpac
science
anpac
bio
company
nasdaq
anpc
biotechnology
company
operations
china
united
states
announced
today
company
investee
company
china
jiangsu
anpac
health
management
jiangsu
anpac
jiangsu
anpac
anpac
bio
joint
venture
company
owning
equity
interest
qualified
nucleic
acid
tests
first
half
received
certification
regulatory
authority
october
nucleic
acid
tests
jiangsu
anpac
medical
lab
city
wuxi
jiangsu
province
china
jiangsu
anpac
begun
receive
samples
paid
nucleic
acid
tests
recently
anpac
bio
jiangsu
anpac
signed
agreement
develop
qualify
new
test
technologies
products
carry
evaluations
jiangsu
anpac
medical
lab
global
cases
still
rising
possibility
reoccurrence
tests
likely
become
widely
needed
long
term
critical
tests
addition
novel
cancer
screening
technology
products
services
anpac
bio
also
active
test
products
services
commercialization
program
us
china
including
key
patent
application
filed
year
company
san
jose
lab
commercializing
antibody
test
quarter
active
test
development
evaluation
program
nucleic
acid
test
certified
jiangsu
anpac
medical
lab
anpac
bio
ceo
chris
yu
commented
addition
successful
launch
immunology
test
product
first
half
year
qualification
commercialization
tests
another
major
achievement
anpac
bio
year
addition
mentioned
new
products
services
novel
biophysics
based
cancer
differentiation
analysis
cda
cancer
screening
tests
anpac
bio
poised
offer
customers
market
much
broader
set
products
services
contribute
revenue
growth
significantly
next
years
anpac
bio
anpac
bio
biotechnology
company
focused
early
cancer
screening
detection
issued
patents
june
two
certified
clinical
laboratories
china
one
clia
cap
accredited
clinical
laboratory
united
states
anpac
bio
performs
suite
cancer
screening
detection
tests
including
cda
cancer
differentiation
analysis
immunological
genomics
tests
according
frost
sullivan
anpac
bio
ranked
third
worldwide
first
china
among
companies
offering
early
cancer
screening
detection
technologies
terms
number
clinical
samples
cancer
screening
detection
based
approximately
clinical
samples
may
anpac
bio
cda
technology
platform
shown
retrospective
validation
studies
able
detect
risk
different
cancer
types
high
sensitivity
specificity
information
please
visit
https
investor
media
inquiries
please
contact
company
phil
case
marketing
investor
relations
phone
us
email
investor
relations
ascent
investor
relations
llc
tina
xiao
president
phone
us
email
safe
harbor
statement
announcement
contains
statements
within
meaning
section
securities
act
section
securities
exchange
act
statements
made
safe
harbor
provisions
private
securities
litigation
reform
act
relating
company
future
financial
operating
performance
company
attempted
identify
statements
terminologies
including
believes
estimates
anticipates
expects
plans
projects
intends
potential
target
aim
predict
outlook
seek
goal
objective
assume
contemplate
continue
positioned
forecast
likely
may
could
might
approximately
words
convey
uncertainty
future
events
outcomes
identify
statements
statements
based
current
expectations
assumptions
uncertainties
involving
judgments
among
things
future
economic
competitive
market
conditions
future
business
decisions
difficult
impossible
predict
accurately
many
beyond
company
control
statements
also
involve
known
unknown
risks
uncertainties
factors
may
cause
company
actual
results
materially
different
expressed
implied
statement
known
unknown
risks
uncertainties
factors
include
limited
implementation
business
model
growth
strategies
trends
competition
cancer
screening
detection
market
expectations
regarding
demand
market
acceptance
cancer
screening
detection
tests
ability
expand
customer
base
ability
obtain
maintain
intellectual
property
protections
cda
technology
continued
research
development
keep
pace
technology
developments
ability
obtain
maintain
regulatory
approvals
nmpa
fda
relevant
states
laboratories
certified
accredited
authorities
including
clia
future
business
development
financial
condition
results
operations
ability
obtain
financing
potential
changes
government
regulations
general
economic
business
conditions
china
elsewhere
ability
hire
maintain
key
personnel
relationship
major
business
partners
customers
duration
coronavirus
outbreaks
potential
adverse
impact
economic
conditions
financial
markets
business
financial
performance
resulting
reduced
commercial
activities
due
quarantines
travel
restrictions
instituted
china
many
countries
around
world
contain
spread
virus
additionally
statements
subject
risk
factors
detailed
time
time
company
recent
annual
report
form
filings
securities
exchange
commission
risks
uncertainties
assumptions
undue
reliance
placed
statements
addition
statements
speak
date
press
release
except
may
required
law
company
undertakes
obligation
revise
update
publicly
statements
reason
